OMGA · Omega Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.61M | $759.0K | $2.36M | - | $595.0K | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.81M | $12.94M | $15.41M | - | $16.48M | $25.01M | $19.97M | - | $20.67M | $19.39M |
| SG&A | $6.22M | $5.77M | $7.40M | - | $7.87M | $6.21M | $5.95M | - | $5.20M | $6.20M |
| Total Operating Expenses | $19.03M | $18.71M | $22.81M | - | $23.73M | $31.60M | $26.33M | - | $26.58M | $26.33M |
| D&A | $400.0K | $500.0K | $443.0K | - | $400.0K | $300.0K | $371.0K | - | - | $400.0K |
| Operating Income | ($16.42M) | ($16.58M) | ($20.45M) | - | ($22.90M) | ($30.84M) | ($25.82M) | - | ($25.98M) | ($25.85M) |
| Interest Expense | $384.0K | $406.0K | $430.0K | - | $482.0K | $456.0K | $420.0K | - | $308.0K | $55.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($16.44M) | ($16.30M) | ($20.13M) | - | ($22.25M) | ($29.69M) | ($25.28M) | - | ($25.80M) | ($25.91M) |
| EPS - Basic | ($0.30) | ($0.30) | ($0.36) | - | ($0.40) | ($0.54) | ($0.42) | - | ($0.57) | ($3.36) |
| EPS - Diluted | ($0.30) | ($0.30) | ($0.36) | - | ($0.40) | ($0.54) | ($0.50) | - | ($0.57) | ($0.54) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.38M | $45.85M | $60.03M | $68.44M | $81.77M | $105.54M | $104.54M | $70.61M | $76.61M | $90.86M |
| Accounts Receivable | - | - | - | $5.13M | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.43M | $1.72M | $1.58M | $1.62M | $2.40M | $6.33M | $3.68M | $3.11M | $2.57M | $2.73M |
| Current Assets | $38.95M | $56.06M | $70.89M | $89.88M | $101.90M | $124.93M | $148.85M | $137.59M | $161.04M | $183.08M |
| Total Assets | $152.73M | $168.22M | $183.68M | $204.37M | $217.81M | $229.02M | $156.31M | $146.00M | $170.06M | $193.05M |
| Current Liabilities | $24.17M | $25.54M | $24.68M | $26.81M | $26.82M | $33.66M | $18.10M | $21.96M | $14.70M | $13.61M |
| Long-term Debt | $11.59M | $12.91M | $13.90M | $14.88M | $15.86M | $11.62M | $14.11M | $16.60M | $19.90M | $19.89M |
| Total Liabilities | $141.18M | $141.96M | $142.33M | $146.35M | $141.76M | $133.10M | $33.31M | $40.03M | $36.41M | $35.66M |
| Stockholders' Equity | $11.54M | $26.26M | $41.35M | $58.02M | $76.04M | $95.92M | $123.00M | $105.97M | $133.65M | $157.38M |
| Retained Earnings | ($387.51M) | ($371.07M) | ($354.76M) | ($334.63M) | ($314.42M) | ($292.17M) | ($262.49M) | ($237.21M) | ($206.38M) | ($180.58M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($11.80M) | - | - | - | ($28.11M) | - | - | - |
| Investing Cash Flow | - | - | $4.46M | - | - | - | $22.05M | - | - | - |
| Financing Cash Flow | - | - | ($1.07M) | - | - | - | $39.99M | - | - | - |
| CapEx | - | - | $535.0K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($12.34M) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -628.6% | -2184.5% | -866.6% | - | -3849.2% | - | - | - | - | - |
| EBITDA margin | -613.3% | -2118.6% | -847.8% | - | -3782.0% | - | - | - | - | - |
| Net margin | -629.6% | -2148.2% | -852.9% | - | -3739.2% | - | - | - | - | - |
| Free cash flow margin | - | - | -522.9% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.61 | - | - | - | - | - | - | - |
| R&D / Revenue | 490.3% | 1704.9% | 653.2% | - | 2768.9% | - | - | - | - | - |
| SG&A / Revenue | 238.3% | 760.7% | 313.4% | - | 1322.5% | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.8% | -9.7% | -11.0% | - | -10.2% | -13.0% | -16.2% | - | -15.2% | -13.4% |
| Return on equity | -142.5% | -62.1% | -48.7% | - | -29.3% | -31.0% | -20.6% | - | -19.3% | -16.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.61 | 2.19 | 2.87 | 3.35 | 3.80 | 3.71 | 8.22 | 6.26 | 10.96 | 13.46 |
| Quick ratio | 1.61 | 2.19 | 2.87 | 3.35 | 3.80 | 3.71 | 8.22 | 6.26 | 10.96 | 13.46 |
| Cash ratio | 1.26 | 1.80 | 2.43 | 2.55 | 3.05 | 3.14 | 5.77 | 3.22 | 5.21 | 6.68 |
| Leverage | ||||||||||
| Debt / Equity | 1.00 | 0.49 | 0.34 | 0.26 | 0.21 | 0.12 | 0.11 | 0.16 | 0.15 | 0.13 |
| Debt / Assets | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.05 | 0.09 | 0.11 | 0.12 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -42.8x | -40.8x | -47.6x | - | -47.5x | -67.6x | -61.5x | - | -84.4x | -470.1x |
| Equity multiplier | 13.23 | 6.41 | 4.44 | 3.52 | 2.86 | 2.39 | 1.27 | 1.38 | 1.27 | 1.23 |
| Liabilities / Assets | 0.92 | 0.84 | 0.77 | 0.72 | 0.65 | 0.58 | 0.21 | 0.27 | 0.21 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | 0.00 | 0.01 | - | 0.00 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 339.0% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 28.3% | 46.2% | 20.8% | - | 11.9% | -19.3% | -29.4% | - | -223.0% | -70.0% |
| Net income growth (YoY) | 26.1% | 45.1% | 20.4% | - | 13.8% | -14.6% | -25.4% | - | -39.2% | -68.2% |
| EPS growth (YoY) | 25.0% | 44.4% | 28.0% | - | 29.8% | 0.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -84.8% | -72.6% | -66.4% | -45.3% | -43.1% | -39.1% | -32.2% | -47.2% | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Omega Therapeutics against the 5 most active filers in the same SIC group.